DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Nanomedicine Market Analysis By Products, (Therapeutics, Regenerative Medicine, Diagnostics), By Application, (Clinical Oncology, Infectious diseases), By Nanomolecule (Gold, Silver, Iron Oxide, Alumina), & Segment Forecasts, 2013 - 2025" report to their offering.
The global nanomedicine market is anticipated to reach USD 350.8 billion by 2025
Development of novel nanotechnology-based drugs and therapies is driven by the need to develop therapies that have fewer side effects and that are more cost-effective than traditional therapies, in particular for cancer.
Application of nanotechnology-based contrast reagents for diagnosis and monitoring of the effects of drugs on an unprecedented short timescale is also attributive drive growth in the coming years. Additionally, demand for biodegradable implants with longer lifetimes that enable tissue restoration is anticipated to influence demand.
As per the WHO factsheet, cancer is found to be one of the major causes of mortality and morbidity worldwide, with approximately 14 million new cases in 2012 and 8.2 million cancer-related deaths. Thus, demand for nanomedicine in order to curb such high incidence rate is expected to boost market progress during the forecast period.
Solutions such as nanoformulations with triggered release for tailor-made pharmacokinetics, nanoparticles for local control of tumor in combination with radiotherapy, and functionalized nanoparticles for targeted in-vivo activation of stem cell production are anticipated to drive R&D, consequently resulting in revenue generation in the coming years.
Biopharmaceutical and medical devices companies are actively engaged in development of novel products as demonstrated by the increasingly growing partnerships between leading enterprises and nanomedicine startups. For instance, in November 2015, Ablynx and Novo Nordisk signed a global collaboration and a licensing agreement for development and discovery of innovative drugs with multi-specific nanobodies. This strategic partnership is anticipated to rise the net annual sales of the products uplifting the market growth.
However, in contrary with the applications of nanotechnology, the entire process of lab to market approval is a tedious and expensive one with stringent regulatory evaluation involved thereby leading investors to remain hesitant for investments.
Key Topics Covered:
1 Research Methodology
2 Executive Summary
3 Nanomedicine Market Variables, Trends & Scope
4 Nanomedicine Market: Product Estimates & Trend Analysis
5 Nanomedicine Market: Application Estimates & Trend Analysis
6 Nanomedicine Market: Nanomolecule Type Estimates & Trend Analysis
7 Nanomedicine Market: Regional Estimates & Trend Analysis, by Product, Application, & Nanomolecule Type
8 Competitive Landscape
- CALANDO PHARMACEUTICALS, Inc.
- Brigham and Women's Hospital (BWH)
- Nanospectra Biosciences, Inc.
- ABLYNX
- AMAG Pharmaceuticals
- Bio-Gate AG
- Celgene Corporation
- Abraxis BioScience, Inc.
- Johnson & Johnson Services, Inc.
- Pfizer, Inc.
- Abbott
- Leadiant Biosciences, Inc.
- Teva Pharmaceutical Industries Ltd.
- CYTIMMUNE SCIENCES, INC.
- Merck & Co Ltd
- Gilead
- Epeius Biotechnologies Corporation
For more information about this report visit http://www.researchandmarkets.com/research/6fcvtv/nanomedicine
